HomeNews & TopicsResearchPharmaceutical drug security should be a priority in Canada

Pharmaceutical drug security should be a priority in Canada

Published on

Shortages of essential medicines threaten Canadians’ health and ensuring access to critical drugs at all times should be a government priority, write authors in an analysis in CMAJ (Canadian Medical Association Journal).

“Canada’s pharmaceutical supply has become highly dependent on foreign imports and vulnerable supply chains and recent Canadian investments for pandemic preparedness do not address the entirety of pharmaceutical shortcomings,” writes Dr. Shoo Lee, Department of Paediatrics, University of Toronto and Mount Sinai Hospital, Toronto, with coauthors. “A cohesive national policy is needed to address this problem.”

For more than a decade, Canada has experienced ongoing drug shortages, such as the shortage of epinephrine self-injectors (i.e., EpiPens) over the last five years, and recent shortages of hydroxychloroquine for the treatment of rheumatoid arthritis and inflammatory bowel disease owing to use by some to treat COVID-19.

Canada’s pharmaceutical market is small, making up just 2% ($18 billion USD) of total global revenue in 2019. The country relies heavily on imported medications, making it vulnerable to supply chain disruptions and drug shortages. In June 2022, 23 Tier 3 drugs were in short supply; this category includes critical drugs with the potential for the greatest negative impact on drug supply and the health system.

The authors suggest several steps to improve the security of pharmaceutical drugs in Canada including:

  • Developing a list of medicines essential to prevent death or severe illness
  • Stockpiling these medications in the national emergency strategic stockpile (NESS) or requiring drug companies to do so
  • Strengthening domestic manufacturing of pharmaceuticals
  • Collaborating with international partners to strengthen supply chains

“Investment in API [active pharmaceutical ingredient] and pharmaceutical manufacturing technologies should be integral to Canada’s strategy to become pharmaceutically self-sufficient,” they write.

“Pharmaceutical security for Canada” is published August 22, 2022.

Latest articles

How AI could help or hinder Canada’s health care system

HN Summary • AI could help address Canada’s healthcare staffing crisis by improving efficiency, triage,...

Patient care runs on mobile devices. Is your fleet holding you back?

Dead batteries. Lost devices. Outdated software. Rising security threats.  These are all mobility threats that...

On National Caregivers Day, ALS Canada expands national mental health supports for caregivers with funding from Petro‑Canada CareMakers Foundation

Virtual program connects caregivers to mental health support anywhere in Canada. In recognition of National...

Cancer clinicians call for three actions Canada’s health systems should take to improve cancer care

April Cancer Awareness Month a good time for concrete action The Cancer Clinician Advocacy Forum...

More like this

This Canadian startup is decoding the health data revealed in our eyes

If you’ve had a fluorescein angiography (FA), chances are you remember it. The procedure...

A new home for Canada’s largest Cancer Research Tumour Bank

Decades of cancer research — and thousands of patient tumour samples — now have...

Equity-focused study on immigrant kidney disease risk

HN Summary • A new SHN-led study published in BMJ Open reveals significant disparities in...

Shorter duration of antimicrobial therapy in common infections

HN Summary • Growing evidence shows that shorter courses of antibiotics are just as effective...

Global clinical trial exploring potential treatment for sickle cell disease

HN Summary • SHN is leading a global clinical trial testing tebapivat, an investigational oral...

Lithium study yields insights in the fight against HIV

Study in human cells finds low-cost drug keeps virus dormant through an unexpected pathway,...